Education
About Us
Working with TipRanks
Follow Us
Syndax Pharmaceuticals Inc (SNDX)
NASDAQ:SNDX
SNDX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.58 - $22.50
Previous CloseN/A
Volume201.89K
Average Volume (3M)2.62M
Market Cap
$1.41B
Enterprise Value$698.84M
Total Cash (Recent Filing)$468.71M
Total Debt (Recent Filing)$1.68M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Nov 11, 2025EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding86,141,860
10 Day Avg. Volume1,813,167
30 Day Avg. Volume2,620,181
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.50
Enterprise Value/Revenue8.94
Enterprise Value/Gross Profit9.29
Enterprise Value/Ebitda-2.18
Forecast
1Y Price Target
$34.09Price Target Upside119.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Bulls Say, Bears Say
Bulls Say
Commercial LaunchThe recent commercial launches of two assets, each with over $1 billion peak sales potential, create a path to profitability and form the basis of a compelling valuation-based thesis.
Market PositionRevuforj is competitively best-positioned to capture a majority of the $5 billion peak U.S. sales potential for the menin inhibitor class, with a first-mover advantage in leukemia treatment.
Revenue Growth2Q25 revenue of ~$38M beat our estimates by >70% (and VA consensus by ~45%), driven by Revuforj’s 43% growth QoQ and Niktimvo which is already profitable to SNDX.
Bears Say
Market ExpectationsContinued commercial execution over quarterly reports is crucial for SNDX's stock, and management's success in this area could lead to a re-rating of the stock.
Stock ValuationThe market continues to substantially undervalue SNDX with the stock trading at a deep discount vs. strong and only improving fundamentals.
Syndax Pharmaceuticals News
SNDX FAQ
What was Syndax Pharmaceuticals Inc’s price range in the past 12 months?
Syndax Pharmaceuticals Inc lowest stock price was $8.58 and its highest was $22.50 in the past 12 months.
What is Syndax Pharmaceuticals Inc’s market cap?
Syndax Pharmaceuticals Inc’s market cap is $1.41B.
When is Syndax Pharmaceuticals Inc’s upcoming earnings report date?
Syndax Pharmaceuticals Inc’s upcoming earnings report date is Nov 11, 2025 which is in 58 days.
How were Syndax Pharmaceuticals Inc’s earnings last quarter?
Syndax Pharmaceuticals Inc released its earnings results on Aug 04, 2025. The company reported -$0.83 earnings per share for the quarter, beating the consensus estimate of -$1.016 by $0.186.
Is Syndax Pharmaceuticals Inc overvalued?
According to Wall Street analysts Syndax Pharmaceuticals Inc’s price is currently Undervalued.
Does Syndax Pharmaceuticals Inc pay dividends?
Syndax Pharmaceuticals Inc does not currently pay dividends.
What is Syndax Pharmaceuticals Inc’s EPS estimate?
Syndax Pharmaceuticals Inc’s EPS estimate is -0.72.
How many shares outstanding does Syndax Pharmaceuticals Inc have?
Syndax Pharmaceuticals Inc has 86,141,860 shares outstanding.
What happened to Syndax Pharmaceuticals Inc’s price movement after its last earnings report?
Syndax Pharmaceuticals Inc reported an EPS of -$0.83 in its last earnings report, beating expectations of -$1.016. Following the earnings report the stock price went up 21.098%.
Which hedge fund is a major shareholder of Syndax Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in SNDX
Syndax Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.09 (119.23% Upside)
$34.09 (119.23% Upside)
Blogger Sentiment
Bullish
SNDX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 292.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $81.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.2%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.56%
12-Months-Change
Fundamentals
Return on Equity
-113.22%
Trailing 12-Months
Asset Growth
24.99%
Trailing 12-Months
Company Description
Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for cancer treatment. The company operates primarily in the biotechnology sector, with a commitment to discovering, developing, and delivering novel therapies that address unmet needs in oncology. Its core products include a pipeline of drug candidates designed to enhance the effectiveness of existing cancer treatments and improve patient outcomes.
SNDX Company Deck
SNDX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance with significant revenue growth and strategic advancements in pipeline and market expansion. The company shows a clear path to profitability with stable operating expenses and promising future opportunities. However, there are some dependencies on regulatory approvals and expectations for increased transplant rates.View all SNDX earnings summariesSNDX Stock 12 Month Forecast
Average Price Target
$34.09
▲(119.23% Upside)
Technical Analysis
Ownership Overview
1.37% Insiders
14.17% Mutual Funds
54.13% Other Institutional Investors
17.60% Public Companies and Individual Investors